We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
10
4 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2008
Active, not recruiting
3
30.0%
Completed
2
20.0%
Not yet recruiting
1
10.0%
Recruiting
4
40.0%
No approval data available
- DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape. - Several promising late-stage candidates are advancing through Phase III trials, including Cadisegliatin (vTv Therapeutics) for type 1 diabetes and Insulin efsitora alfa (Eli Lilly) as a once-weekly basal insulin. - Recent clinical trial announcements from major pharmaceutical companies demonstrate continued investment in diabetes research, with studies comparing novel formulations and combination therapies. - The pipeline encompasses diverse therapeutic approaches including liver-selective glucokinase activators, ultra-rapid-acting insulin analogs, and oral GLP-1 receptor agonists targeting different aspects of diabetes management.
